Latest Commercial Growth News

RLF AgTech is advancing its commercial growth strategy by expanding its nutrition and biologicals portfolio and rebuilding its Australian sales function, achieving a six-fold increase in customer receipts since early 2026.

Webjet Group has appointed Nicole Sheffield as its new Managing Director and CEO, aiming to leverage her extensive digital and commercial leadership experience to advance the company’s growth and innovation agenda.

First Graphene has signed an MOU with Sixth Element to distribute its PureGRAPH® CEM additive across China, with potential for local manufacturing via a joint venture once sales milestones are met.

Dataworks Group has arranged a $1.5 million unsecured working capital facility with a three-month term and 18% interest, aiming to strengthen liquidity and support ongoing and new commercial contracts without diluting equity.

Wide Open Agriculture is closing its German plant and pivoting to contract manufacturing in Asia to cut costs and scale lupin ingredient production efficiently under new CEO Craig Swan.

Control Bionics has locked in $9.5 million through a discounted share placement, complemented by a $0.5 million Share Purchase Plan, to back its commercial growth and technology development.

Dotz Nano has secured A$3.3 million through a private placement, backing its next phase of production scale-up and customer engagement under incoming CEO Nati Harpaz.

InteliCare (ASX:ICR) is hitting a commercial inflection point, backed by a landmark $8.8 million contract with mecwacare and a growing pipeline across aged care sectors. Its AI-powered platform promises measurable improvements in care outcomes and operational efficiency.

Wesfarmers outlines a bold growth and productivity agenda centred on AI integration, expanding retail footprints, and lithium project progress, underpinning strong shareholder returns and portfolio resilience.

ImpediMed has revamped its leadership with two new commercial roles and reported encouraging sales momentum for its SOZO device. The company is advancing clinical trials and expanding its presence in cancer survivorship, weight management, and heart health sectors.

Tetratherix Limited secures $15 million via institutional placement plus a capped $2 million share purchase plan at a 14% discount, aiming to fast-track manufacturing expansion and commercial partnerships.

Pathkey.AI appoints Andrew Farnsworth as CEO, leveraging his defence and AI expertise to drive commercialisation of TrialKey and Chipforge platforms.